Alphabet subsidiary GV was part of a consortium in a round that will fund the progress of the precision medicine developer's lead drug candidate into the clinic.

The operator of the online marketplace platform for electronic components has pulled in new funding from existing investor JD.com.

SIG China joined two China-based venture capital firms in the mobile sandbox platform developer's series C round.

China Merchants Group led a series C round for the antibody drug developer that was also backed by fellow corporates Tigermed and Dawn.

Tencent co-led the real estate portal operator’s series C-plus round, which also featured Eight Roads Ventures, Sequoia Capital China and Source Code Capital.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Verizon Ventures has returned to back the transport management technology developer in a series C round reportedly valuing it at up to $500m.

The commercial insurer has raised $147m to date, with existing backers including Telstra investing at a $750m valuation.

Sany Group and Fosun contributed to a $61.4m round for the third-party drug development services provider, which counts Jilin Aodong Medicine as an earlier backer.

Deutsche Telekom has participated in another round for the cybersecurity software developer, which is also backed by Merlin International.